Medivector Inc. of Boston, Massachusetts, was awarded a $30,000,000 cost-plus-incentive-fee contract for Phase 2 clinical trials for efficacy testing to include any associated data as may be useful for the Investigational New Drug filing of the product Favipiravir which is directed at development of a medical countermeasure against a validated biological warfare agent (Ebola).
Work will be performed in Boston, MA and in Africa. Fiscal 2015 research, development, testing and evaluation funds in the amount of $7,900,000 are being obligated at the time of the award. Army Contracting Command, Natick, Massachusetts, is the contracting activity (W911QY-15-C-0011).
Source: Defense.gov